Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV001726756 | SCV001961117 | uncertain significance | not provided | 2021-07-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001882791 | SCV002315332 | uncertain significance | Juvenile onset Parkinson disease 19A | 2022-11-01 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 277 of the DNAJC6 protein (p.Ala277Thr). This variant is present in population databases (rs146050826, gnomAD 0.08%). This variant has not been reported in the literature in individuals affected with DNAJC6-related conditions. ClinVar contains an entry for this variant (Variation ID: 1298426). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The threonine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV001726756 | SCV002759075 | uncertain significance | not provided | 2022-06-01 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Genome- |
RCV001882791 | SCV004049375 | uncertain significance | Juvenile onset Parkinson disease 19A | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004039994 | SCV004860148 | uncertain significance | Inborn genetic diseases | 2022-01-28 | criteria provided, single submitter | clinical testing | The c.658G>A (p.A220T) alteration is located in exon 7 (coding exon 7) of the DNAJC6 gene. This alteration results from a G to A substitution at nucleotide position 658, causing the alanine (A) at amino acid position 220 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Breakthrough Genomics, |
RCV001726756 | SCV005186739 | uncertain significance | not provided | criteria provided, single submitter | not provided |